MedTrace Logo

sgp130 in Chronic Human Liver Disease

NCT00770198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2008-10-09

No results posted yet for this study

Summary

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Conditions

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Arnaud Lemmers, MD · Erasme Hospital, Gastroenterology Dpt

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-01-31
Completion
2008-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770198 on ClinicalTrials.gov